Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 13.23M | 6.93M | 12.11M | 15.99M | 14.10M |
Gross Profit | 10.42M | -3.53M | 10.66M | 4.88M | 3.37M |
EBITDA | -5.03M | -8.83M | -340.00K | 2.75M | 721.00K |
Net Income | -5.41M | -8.50M | -1.16M | 2.10M | -1.92M |
Balance Sheet | |||||
Total Assets | 31.37M | 28.29M | 30.08M | 34.13M | 28.59M |
Cash, Cash Equivalents and Short-Term Investments | 904.00K | 4.43M | 9.21M | 6.93M | 6.86M |
Total Debt | 4.47M | 740.00K | 881.00K | 766.00K | 5.00K |
Total Liabilities | 7.93M | 4.15M | 3.46M | 6.51M | 5.29M |
Stockholders Equity | 23.44M | 24.14M | 26.63M | 27.61M | 23.30M |
Cash Flow | |||||
Free Cash Flow | -10.30M | -8.42M | 1.95M | -156.00K | -2.65M |
Operating Cash Flow | -9.60M | -7.90M | 2.86M | 370.00K | -1.89M |
Investing Cash Flow | -1.09M | -522.00K | -912.00K | -526.00K | -761.00K |
Financing Cash Flow | 6.77M | 3.64M | 337.00K | 224.00K | 12.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
50 Neutral | AU$2.62B | 3.32 | -57.47% | 2.40% | 36.73% | 13.67% | |
46 Neutral | AU$40.03M | ― | -19.31% | ― | 72.25% | 43.66% | |
― | $27.95M | ― | -130.18% | ― | ― | ― | |
― | AU$33.53M | 10.00 | 4.10% | ― | ― | ― | |
63 Neutral | AU$43.05M | 19.12 | 4.85% | ― | 5.76% | -79.76% | |
53 Neutral | AU$23.03M | ― | -218.38% | ― | -14.30% | 29.69% | |
41 Neutral | AU$74.35M | ― | -45.40% | ― | 13.61% | -55.12% |
IDT Australia Limited announced the cessation of 861,000 ordinary fully paid securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could have implications for its market positioning and stakeholder interests.
IDT Australia Limited reported a 30% increase in quarterly revenue, reaching $4.1 million, driven by new contract wins and a strong pipeline of potential contracts totaling $62 million. The company experienced significant growth in its Active Pharmaceutical Ingredients vertical, which is expected to positively impact its Advanced Therapies and Specialty Orals segments. Despite global trade uncertainties, IDT’s outlook remains positive, with new contracts and proposals indicating robust future growth opportunities.